Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference Life Science Investing
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data Life Science Investing
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society Congress Life Science Investing
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides Life Science Investing
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP Platform Presented at the 2026 ASCO Annual Meeting Life Science Investing
PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study Life Science Investing
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference Life Science Investing
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference Life Science Investing
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza Life Science Investing
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference Life Science Investing
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 Life Science Investing
Dyne Therapeutics Announces Submission of Biologics License Application to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy Life Science Investing
